Hematology/Oncology Specialist - Milwaukee, WI

USA (Unknown)

$170K/yr – $210K/yrSenior Level5+ years expFull time

Posted 2 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and execute regional business plans, drive product access and sales in oncology, build KOL relationships, and collaborate with cross-functional teams to bring Karyopharm therapies to patients.

  • Lead market analysis and strategy linked to sales goals
  • Develop patient access strategies and coordinate with Market Access and Medical Affairs
  • Build clinical and technical expertise and nurture relationships with key stakeholders

Job Description

Responsibilities

  • Develop business plans, market analysis, and strategy that link to strong business results and execute accordingly
  • Position on-label benefits for appropriate patients to key customer stakeholders to achieve or exceed forecasted sales goals
  • Resolve issues at account level to ensure access to therapy
  • Coordinate with colleagues in cross-functional areas including Market Access, Clinical Education, and Medical Affairs to facilitate customer and patient access to Karyopharm product(s) and information
  • Provide customer feedback to internal stakeholders, sharing best practices, unmet needs, and business opportunities
  • Assist Marketing function in identifying and inviting appropriate healthcare professionals (HCPs) to promotional and educational events or programs
  • Develop and maintain mastery of clinical and technical knowledge related to product(s) promoted, the oncology marketplace, and disease management
  • Foster and develop relationships with Key Opinion Leaders (KOLs), decision makers, influencers, and key stakeholders within the oncology community
  • Deliver clinical and technical value at medical meetings by staffing promotional booths, as requested
  • Comply with all laws and regulations and adhere to company compliance guidelines, policy and procedures

Requirements

  • Bachelor’s degree, required
  • 5+ years of pharmaceutical sales experience, with a documented history of success
  • 2+ years’ oncology or rare disease pharmaceutical sales experience, including product launch(es)
  • Experience in Hematology and/or Multiple Myeloma preferred
  • Must reside in close proximity to the geography or be willing to relocate to it
  • Valid driver's license and the ability to travel as necessary

Preferred

  • Existing relationships with oncology practices in territory, preferred
  • 5+ years of oncology or rare disease pharmaceutical sales experience, including product launch(es) (already in requirements; keep as nice_to_have? first line is optional)

Benefits

  • comprehensive benefits (medical, dental, vision, 401(k), and more), equity and the potential to receive annual target bonuses.
Karyopharm Therapeutics logo

Karyopharm Therapeutics

3.9 Glassdoor

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a focused pipeline that targets multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer,myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

Founded in 2008
Newton Centre, Massachusetts, USA
312 employees (6 in marketing)
77% recommend to a friend
89% CEO approval

Traffic Signals

Monthly Visitors
8.9K
Traffic Source Mix
Search
38.5%
Direct
44.4%
Referral
6.4%
Social
9.3%
Paid
1.3%

Headcount Trend

Current headcount: ~312

Marketing Team

Marketing Team Size
6 (2% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$637.2M
Last Raise
$30M
Post IPO Equity, 3 months ago

Funding History

  • Mar 2026
    Post IPO Equity • $30M
  • Oct 2025
    Post IPO Equity • $33M
  • Oct 2025
    Post IPO Debt • $27.5M

Recent News